Location History:
- Gradignan, FR (2007 - 2013)
- Talence, FR (2013 - 2015)
Company Filing History:
3 out of 213 
2 out of 3,559 
2 out of 1,746 
Years Active: 2007-2015
Title: The Innovations of Andreas Bikfalvi
Introduction
Andreas Bikfalvi is a notable inventor based in Talence, France. He has made significant contributions to the field of biotechnology, particularly in the area of anti-angiogenic therapies. With a total of 4 patents to his name, his work has the potential to impact various medical applications.
Latest Patents
One of his latest patents involves mutants of PF4 polypeptides that exhibit increased anti-angiogenic activity. This invention pertains to PF4 muteins which comprise a substitution at position 67, such as a L67H substitution, compared to the sequence of the wild-type PF4 protein. These PF4 muteins demonstrate enhanced anti-angiogenic activity and a reduced affinity for proteoglycans compared to the wild-type PF4 protein. Another significant patent focuses on neutralizing antibodies and fragments directed against Platelet Factor-4 variant 1 (PF4V1). This invention relates to the use of these antibodies for treating pathologies that require the induction of angiogenesis or diseases associated with pathological angiogenesis.
Career Highlights
Throughout his career, Andreas Bikfalvi has worked with esteemed institutions such as Université de Bordeaux and Commissariat à l'Énergie Atomique. His research has been pivotal in advancing our understanding of angiogenesis and its implications in various diseases.
Collaborations
Andreas has collaborated with notable colleagues, including Natacha Betz and Gerard Deleris, further enhancing the impact of his research through teamwork and shared expertise.
Conclusion
Andreas Bikfalvi's innovative work in the field of biotechnology, particularly in anti-angiogenic therapies, showcases his dedication to advancing medical science. His patents and collaborations reflect a commitment to improving health outcomes through research and innovation.